Patients with psoriasis report improvements with tapinarof cream

Patients treated with once-daily tapinarof cream 1% for mild to severe plaque psoriasis reported positive outcomes, according to two phase 3 studies.

A novel therapeutic aryl hydrocarbon receptor modulating agent, tapinarof is being developed for both psoriasis and atopic dermatitis treatment.

The PSOARING 1 and PSOARING 2 trials compared patient-reported outcomes for subjects using tapinarof compared with those using a vehicle cream, Robert Bissonnette, MD, FRCPC, founder and CEO of Innovaderm Research, presented at AAD VMX 2021.

In PSOARING 1 and PSOARING 2, mean PP-NRS scores significantly improved with tapinarof vs vehicle at Week 2 through Week 12: –3.9 vs –2.9 (P=0.0002) and –3.0 vs –1.4 (P<0.0001).

Significant improvements in mean Dermatology Life Quality Index were achieved by Week 4 with minimal clinically important difference (–4.0) at Week 12 for patients treated with tapinarof vs vehicle: –5.0 vs –3.0 and –4.7 vs –1.6 (both P<0.0001).

“Tapinarof cream 1% QD demonstrated rapid, statistically significant and clinically meaningful improvements in patient-reported outcomes consistent with previously reported significant clinical efficacy and good tolerability,” the authors wrote.